Dicloxacillin: Clinical Relevance of Drug-drug Interactions by Induction of Drug Metabolism.

Overview

This trial is conducted as a cocktail-study namely an open-label, randomized, two-sequence, two-period crossover, cocktail study where a combination of cocktail-drugs is used to illustrate whether or not, or to what degree dicloxacillin affects the level of activity of the 5 most important CYP enzymes and therefore plays a potentially decisive role in serious drug-drug interactions.

Full Title of Study: “Dicloxacillin: Clinical Relevance of Drug-drug Interactions by Induction of Drug Metabolizing Enzymes.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 5, 2017

Detailed Description

Given knowledge explains dicloxacillin and the drug warfarin to be a potential dangerous drug drug interaction because the effects of warfarin is downregulated to a degree as to where it might cause patients to have thrombotic events. A potential explanation to this is namely dicloxacillin increases the activity of certain drug metabolising enzymes metabolising warfaring which in turn decreases the concentration of the drug in the blood and the therapeutic effect. Cocktail study is the golden standard to investigate as to whether there is changes is P450 enzymes as a result of drug-drug interactions. The cocktail consists of Midazolam, omeprazole, tolbutamide, caffein and dextromethorphan which is well known markers for these enzymes. These markers are safe, have specific (enzyme) metabolism and has been used in several studies with no Serious Adverse reactions reported. By measuring the Concentration of the drug and its metabolites in plasma / Urine before and after treatment with dicloxacillin we will estimate AUC (area under the curve) and test our hypothesis/primary end point of whether there is change in AUC for Tolbutamide (CYP2C9)

Interventions

  • Drug: Dicloxacillin
    • Tablets containing dicloxacillin are taken 500mg 2x 3 times per day, for 10 days. Followed by test-day nr 1 at day 11. Both arms receives both treatments, randomly assigned
  • Drug: Placebos
    • No drug are taken for 10 days. Non-blinded. Followed by test-day nr 1 at day 11. Both arms receives both treatments, randomly assigned

Arms, Groups and Cohorts

  • Active Comparator: Arm of study1
    • Dicloxacillin tablets.
  • Placebo Comparator: Arm of study 2
    • No treatment

Clinical Trial Outcome Measures

Primary Measures

  • AUC(area under the curve) for tolbutamid (CYP2C9), as a result of dicloxacillin-treatment
    • Time Frame: Pharmacological outcome measures at t=0 predose and postdose; 0.5,1,2,3,4,6,8,10,12,24.
    • AUC measurements giving an estimate of activity og the relevant enzymes.

Secondary Measures

  • *AUC(area under the curve) for midazolam (CYP3A4) and dextromethorphan (CYP1A2) omeprazole (CYP2C19) and caffein (CYP1A2)
    • Time Frame: Pharmacological outcome measures at t=0 predose and postdose; 0.5,1,2,3,4,6,8,10,12,24.
  • T(max)
    • Time Frame: Pharmacological outcome measures at t=0 predose and postdose; 0.5,1,2,3,4,6,8,10,12,24.
    • The amount of time that the drug is present at the maximum concentration in serum.
  • C(max) (peak plasma concentration)
    • Time Frame: Pharmacological outcome measures at t=0 predose and postdose; 0.5,1,2,3,4,6,8,10,12,24.
    • The peak serum concentration of a therapeutic drug.
  • Clearance
    • Time Frame: Pharmacological outcome measures at t=0 predose and postdose; 0.5,1,2,3,4,6,8,10,12,24.
    • The volume of plasma from which the drug is completely removed per unit time. Reflects rate of drug elimination divided by plasma concentration.

Participating in This Clinical Trial

Inclusion Criteria

  • Are you in a general healthy condition?; questions asked; Are you healthy in general? 2; Do you have any chronic diseases? 3; Are you taking any medications regularly? 4, Are you taking any medications periodically . 5; Are you taking nutrition supplements, "nature-medicine" or over-the-counter drugs – BMI; range; 18,5-29,9 kg/m2 – eGFR(estimated glomerular filtration rate), ALAT(alanine aminotransferase), bilirubin, hæmoglobin og HbA1c, should be within normal limits or without clinically significantly deviation from these. – Non-Smoker Exclusion Criteria:

  • Hypersensitivity to applied medications. Known allergy to penicillin or type 1-reaction to cefalosporins. – Known allergy to sulfonamides – Clinically relevant intake of receipt-required medication, over-the-counter medication or nutritional supplements. – Chronic or daily intake of alcohol. – Participation in other Intervention-studies

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Per Damkier
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Per Damkier, Professor, head consultant, MD, ph.d. – Odense University Hospital
  • Overall Official(s)
    • Per Damkier, Ph.d., Principal Investigator, Assosiated to department of biochemistry and pharmacology at University of southern denmark, Odense

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.